KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Receivables data on record, last reported at $899.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 20042.86% year-over-year to $899.6 million; the TTM value through Dec 2025 reached $899.6 million, up 20042.86%, while the annual FY2025 figure was $899.6 million, 18210.2% up from the prior year.
  • Receivables reached $899.6 million in Q4 2025 per AMRX's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $1.5 billion in Q3 2025 and bottomed at $1.8 million in Q4 2022.
  • Average Receivables over 5 years is $866.9 million, with a median of $1.0 billion recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 99.73% in 2022, then skyrocketed 20042.86% in 2025.
  • A 5-year view of Receivables shows it stood at $663.8 million in 2021, then tumbled by 99.73% to $1.8 million in 2022, then skyrocketed by 73.2% to $3.2 million in 2023, then skyrocketed by 41.6% to $4.5 million in 2024, then surged by 20042.86% to $899.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $899.6 million in Q4 2025, $1.5 billion in Q3 2025, and $1.3 billion in Q2 2025.